Feb 20, 2018 - Sharp market correction triggered by interest rate concerns creates opportunities.Market transitions into a more typical rally and pullback mode, with a continued firm uptrend.Biotech stocks are exper
Feb 19, 2018 - After a wild and volatile 2 weeks, what to think about for the short trading week to come.The multiple conflicts affecting the markets.2 chart indicators to be aware of.My thoughts and stocks to watch
Feb 19, 2018 - For those new to this series, it is a reboot back by popular request where we aid readers with a longer-term focus in building a diversified biotech portfolio.I provide an early performance update and
Feb 16, 2018 - Array BioPharma (ARRY) needs investors to pay close attention to the stock based on moves in the options market lately.
Feb 14, 2018 -
Feb 13, 2018 - How to Uncover Institutional Buying
Feb 09, 2018 - For those new to this series, it is a reboot back by popular request where we aid readers with a longer-term focus in building a diversified biotech portfolio.I comment on recent market turmoil and ho
Feb 07, 2018 - The broad U.S. market and the biotech sector rebounded today after hitting a key support level. Will the rebound sustain?Interpreting Array Biopharma's (ARRY) COLUMBUS OS data.Interpeting Allergan's o
Feb 07, 2018 - Stifel issues rating change for ARRY
Feb 07, 2018 - Nabriva has a major catalyst coming up. GW Pharmaceuticals’ marketing application for Epidiolex accepted by EMA. ContraVir announces results from early stage study of Hep B candidate TXL.